José Luis Ventura-Gallegos, Alejandro Zentella-Dehesa, Sergio Juárez-Méndez, Edén Víctor Montes-de-Oca-Fuentes, Karina Jácome-López, Anaís Zarco-Mendoza, Georgina Guerrero, Alberto Jose Cabrera-Quintero, Félix Recillas-Targa
Journal: Molecular biology reports 2024;51(1):148
PMID: 38236307
BACKGROUND
ESR1 is expressed by 60-70% of breast tumours. it's a good prognosis factor and the target of hormone therapy. Optimization of ESR1 reactivation therapy is currently ongoing. Here we probe if the transcription factor CTCF plays a role in the differential expression of ESR1 in the breast cancer cell lines MCF-7 (ESR1+) and MDA-MB-231 (ESR1-).
METHODS AND RESULTS
Knockdown of CTCF in MCF-7 resulted in decreased ESR1 gene expression. CTCF binds to the promoter of ESR1 in MCF-7 but not in MDA-MB-231 cells. CTCF ESR1 binding sites are unmethylated in MCF7 but methylated in MDA-MB-231 cells.
CONCLUSION
ESR1 expression in MCF7 cells is dependent on CTCF expression. CTCF can bind to specific regions of the promotor of ESR1 gene in MCF-7 cells but not in MDA-MB-231 cells, this correlates with the methylation status of these regions and could be involved in the transcriptional regulation of ESR1.
© 2024. The Author(s).
Full Text Sources:
Medical:
Miscellaneous:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.